This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This is not the first time the US has dealt with a shortage of this product as back in 2017 there was a nationwide shortage due to manufacturing delays. The current guidance in the Pfizer document states: Limited inventory released direct and to wholesalers/distributors in part or full when available.
This is not the first time the US has dealt with a shortage of this product as back in 2017 there was a nationwide shortage due to manufacturing delays. The current guidance in the Pfizer document states: Limited inventory released direct and to wholesalers/distributors in part or full when available.
In 2017 the authors developed and implemented a procedure requiring an opioid status verification by a pharmacist for all fentanyl patch orders. Documentation within the medical record. This 3-step procedure includes: 1. Determination of indication 2. Review of prior opioid use 3.
Both the prescriber and pharmacist were required to document the source of the patient’s U-500 insulin dose in the electronic record, as well as which device the patient used to draw their U-500 insulin dose at home (U-100 insulin syringe, TB syringes, etc). In phase two, which began in mid 2017, the following enhancements were made: 1.
09.01.01), which went live in January of 2017. Goal 2, Objective 3.1 : Expand the number of sources for and quantity of antibiotic resistance surveillance data collected from inpatient healthcare facilities. The latest antimicrobial stewardship regulations from The Joint Commission went into effect in January 2023.
By incorporating these measures into both inpatient and outpatient quality reporting, CMS is promoting a more equitable health care system and ensuring that interventions are targeted to reduce health disparities. amazonaws.com/s3fs-public/documents/Update_HHS_Disparities_Dept-FY2020.pdf Krieger, N., Ag é nor, M., and Bassett, M.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content